Main Article Content
Coronavirus disease 2019 (COVID-19), which is brought about by novel coronavirus or Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) could be managed mainly by using repurposed antiviral drugs. This review focuses on the utilization of Kabasura Kudineer in asymptomatic or mild symptomatic COVID-19 patients. The databases such as Medline/PubMed Central/PubMed, Google Scholar, Science Direct, EBSCO, Scopus, Web of science, EMBASE, Directory of open access journals (DOAJ), and reference lists have been looked to distinguish articles pertinent to the clinical and in-silico studies assessing the efficacy of Kabasura Kudineer in the management of COVID-19. A few clinical investigations have exhibited the adequacy of Kabasura Kudineer in the management of asymptomatic or mild-symptomatic COVID-19 patients alongside standard care. Additionally, numerous molecular docking studies have been performed to determine the inhibitory capability of phytoconstituents of Kabasura Kudineer against SARS-CoV-2. More randomized controlled clinical trials would further establish the safety and efficacy of Kabasura Kudineer in COVID-19 patients.
Dawson P, Rabold EM, Laws RL, Conners EE, Gharpure R, Yin S, Buono SA, Dasu T, Bhattacharyya S, Westergaard RP, Pray IW. Loss of taste and smell as distinguishing symptoms of coronavirus disease 2019. Clinical Infectious Diseases. 2021 Feb 15;72(4):682-5.
Llorens S, Nava E, Muñoz-López M, Sánchez-Larsen Á, Segura T. Neurological Symptoms of COVID-19: The Zonulin Hypothesis. Frontiers in Immunology. 2021 Apr 26;12:1344.
Abbasinia M, Hormati A, Hossaini SK, Ghomi SY, Zamani F, Afifian M, Ahmadpour S. Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients: An Integrative Review. Gastroenterology Nursing. 2021 Jan; 44(1):E1-E10.
Korkmaz MÖ, Eğilmez OK, Özçelik MA, Güven M. Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection. European Archives of Oto-Rhino-Laryngology. 2021 May; 278(5):1675-85.
Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar‐Mather TP, Dumenco L, Savaria MC, Aung SN, Flanigan T. Predictors of COVID‐19 severity: A literature review. Reviews in Medical Virology. 2021 Jan;31(1):1-10.
Satarker S, Nampoothiri M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Archives of Medical Research. 2020 May 25;51(6): 482-91.
Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D, Kastritis E, Pavlakis GN, Dimopoulos MA. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science. 2021 Dec; 28(1):1-8.
Malik YA. Properties of coronavirus and SARS-CoV-2. The Malaysian journal of pathology. 2020 Apr 1; 42(1):3-11.
Maideen NMP. Recent updates in the pharmacological management of COVID-19. Letters in Applied NanoBioScience. 2021;1:1969-1980.
Maideen NMP. Adjuvant Therapies of COVID-19 - A Literature Review. Coronaviruses. 2020. DOI: 10.2174/2666796702666210121144902.
WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. New England Journal of Medicine. 2021 Feb 11;384(6):497-511.
Ali M, Khan T, Fatima K, Ali QU, Ovais M, Khalil AT, Ullah I, Raza A, Shinwari ZK, Idrees M. Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions. Phytotherapy Research. 2018 Feb;32(2):199-215.
Maideen NM. Prophetic medicine-Nigella Sativa (Black cumin seeds)–potential herb for COVID-19?. Journal of Pharmacopuncture. 2020 Jun 30;23(2):62-70.
Ashraf S, Ashraf S, Ashraf M, Imran MA, Kalsoom L, Siddiqui UN, Farooq I, Habib Z, Ashraf S, Ghufran M, Akram MK. Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial. medRxiv. 2020 Nov 30.
Kumar KN, Divya KG, Mattummal R, Erni B, Sathiyarajeswaran P, Kanakavalli K. Pharmacological Actions of Contents of Kabasura Kudineer-A Siddha Formulation for Fever with Respiratory Illness. Indian Journal of Pharmaceutical Education and Research. 2021 Jan 1;55(1):36-55.
Saravanan J, Devasia N, Gopalasatheeshkumar K, Sanish Devan V, Thanga Koikila K, Sanjay M. Antiinflammatory, antipyretic and antibacterial study of kabasura kudineer choornam. International Journal of Current Advanced Research. 2018;7(2):9992-7.
Arokyaraj DM, Rathiga G. Phytochemicals and pharmacological activities of kabhasura kudineer, nilavembu kudineer, adathodai kudineer-a review. Int J Trans Res Ind Med. 2020; 2(3):41-51.
Mekala P, Murthy TG. Phytochemical screening and pharmacological update on Kabasura Kudineer Choornam and Nilavembu Kudineer Choornam. Journal of Pharmacognosy and Phytochemistry. 2020; 9(3):1031-6.
Rathinam S, Muthiah K, Parameswaran S, Tamilarasan K, Selvarajan E, Ayyasamy U. Analogy of Kaba Suram with COVID-19 Symptoms-A Siddha Literature Review. International Journal of Ayurvedic Medicine.2020 Dec; 11(4):616-21.
Ahmad S, Zahiruddin S, Parveen B, Basist P, Parveen A, Parveen R, Ahmad M. Indian medicinal plants and formulations and their potential against COVID-19–preclinical and clinical research. Frontiers in Pharmacology. 2021 Mar 2; 11:2470.
Chitra SM, Mallika P, Anbu N, NarayanaBabu R, SugunaBai A, Raj RD, Premnath D. An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19–A Randomized Controlled Study. Journal of Ayurveda and Integrative Medicine. 2021 Jan 21.
Srivastava A, Rengaraju M, Srivastava S, Narayan V, Gupta V, Upadhayay R et al. Efficacy of Two Siddha Poly herbal Decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard Allopathy treatment in the management of Mild to Moderate Symptomatic COVID 19 patients-a Double-Blind, Placebo Controlled, Clinical Trial. Research Square; 2021.
Rao A, Ranganatha R, Vikneswaran G, Sagar C, Mathu R, Sherin M, Reddy MR. AYUSH medicine as add-on therapy for mild category COVID-19; an open label randomised, controlled clinical trial. medRxiv. 2020 Dec 11.
Ramya JE, Chandran GS, Alagesan S, Ravichandran M, Victoria S, Devi MR, Antony SJ, Shantaraman K. A Prospective Observational Study of the Outcome of Treatment with Kabasura Kudineer among Patients with SARS-nCOV-2 Infection. International Journal of Nutrition, Pharmacology, Neurological Diseases. 2021 Apr 1;11(2):169-73.
Jamuna D, Sathiyarajeswaran P, Devi MS, Kanakavalli K, Vinod NP, Nirmala A, Ravikumar T, Pathiban P, Babu K, Dhanam C. Survival analysis to assess the length of stay of novel coronavirus (COVID-19) patients under Integrated Medicine-Zinc, Vitamin C & Kabasura Kudineer (ZVcKK). European Journal of Molecular & Clinical Medicine. 2021 Jan 13;7(10):1375-87.
Bala D. Attitudes, beliefs, and self-use of Kabasura Kudineer among urban and rural population in Tamil Nadu, India: A comparative cross-sectional study. Journal of Family Medicine and Primary Care. 2021 Jan; 10(1):158.
Natarajan S, Anbarasi C, Sathiyarajeswaran P, Manickam P, Geetha S, Kathiravan R, Prathiba P, Pitchiahkumar M, Parthiban P, Kanakavalli K, Balaji P. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Dec;21(1):1-2.
Srivastava A, Rengaraju M, Srivastava S, Narayan V, Gupta V, Upadhayay R. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients-a structured summary of a study protocol for a randomized controlled trial. Trials. 2021 Dec;22(1):1-3.
Bhapkar V, Sawant T, Bhalerao S. A critical analysis of CTRI registered AYUSH studies for COVID-19. Journal of Ayurveda and Integrative Medicine; 2020 Nov 26.
Sundaram KM, Ramasamy MS. Coronavirus spike (S) glycoprotein (2019-ncov) targeted siddha medicines kabasura kudineer and thonthasura kudineer–in silico evidence for corona viral drug. Asian Journal of Pharmaceutical Research and Health Care. 2020 May 18;12(1):20-27.
Kiran G, Karthik L, Devi MS, Sathiyarajeswaran P, Kanakavalli K, Kumar KM, Kumar DR. In silico computational screening of Kabasura Kudineer-official Siddha formulation and JACOM against SARS-CoV-2 spike protein. Journal of Ayurveda and Integrative Medicine; 2020 May 25.
Vincent S, Arokiyaraj S, Saravanan M, Dhanraj M. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro. Frontiers in Molecular Biosciences. 2020; 7. DOI: 10.3389/fmolb.2020.613401.
Lakshmanan K, Moulishankar A, Suresh J. Screening of Kabasura Kudineer Chooranam against COVID-19 through targeting of main protease and RNA-dependent RNA polymerase of SARS-Cov-2 by molecular docking studies; 2020 June 12.
Shah B, Shree Devi MS, Narayanan K, Kanakavalli K, Sathiyarajeswaran P, Karthik L. Repurposing of Medicinal Plants Used in Siddha Formulations As Potential Protease Inhibitors of COVID-19: An in silico Approach; 2020 July 20.
Sivaraman D, selvadoss Pradeep P. Revealing anti-viral potential of Bio-active therapeutics targeting SARS-CoV2-polymerase (RdRp) in combating COVID-19: Molecular Investigation on Indian traditional medicines. Preprints. 2020;2020030450.
Shree Devi MS, Sathiyarajeswaran P, Karthik L, Kanakavalli K, Chandru S, Nipendra Singh. In vitro antiviral activity of Kabasura Kudineer - Siddha Polyherbal Formulation Against Novel Coronavirus (SARS-CoV-2); 2021 May 8.